Physician profile
Marissa E Hogan
NPI 1639621121
$1,700.47
in general payments reported to CMS, 2019-2025
21 companies · $314 in 2025
The $314 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $326 · 2022: $394 · 2023: $407 · 2024: $258 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $980.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $293.46 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $223.71 | 2021-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $211.02 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $189.84 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $141.50 | 2022-2024 | Dificid |
| Glaxosmithkline, LLC. | $98.42 | 2021-2023 | Bexsero, Pediarix, Rotarix |
| Pfizer INC. | $90.99 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.96 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $76.04 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $56.77 | 2021-2023 | Mounjaro |
| Otsuka America Pharmaceutical, INC. | $39.91 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.60 | 2025 | Caplyta |
| Verona Pharma, INC. | $29.13 | 2025 | Ohtuvayre |
| Corcept Therapeutics | $28.92 | 2023 | Korlym |
| Lundbeck LLC | $27.68 | 2025 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $15.94 | 2025 | The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.28 | 2024 | Xifaxan |
| Radius Health, INC. | $13.91 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.88 | 2023 | Jardiance |
| Dexcom, INC. | $13.01 | 2023 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $7.50 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Hogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.